



A Comparison of Adverse Reactions of the First Dose of Gam-COVID-vac (Sputnik V), Oxford/AstraZeneca COVID-19 Vaccine, Bharat Biotech (Covaxin), and (Sinopharm) BBIBP-CorV Vaccines

HamidReza Samimagham ¹, Mehdi Hassani Azad², Mohsen Arabi³, Sobhan Montazer Ghaem⁴, Kimiya Jafari⁴, Dariush Hooshyar ⁴ and Mitra Kazemi Jahromi ^{5,*}

¹Clinical Research Development Center, Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

²Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

³Department of Family Medicine, Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran

⁴Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

⁵Endocrinology and Metablism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

*Corresponding author: Endocrinology and Metablism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Email: mitra.kazemijahromi@gmail.com

Received 2022 January 11; Revised 2022 May 01; Accepted 2022 June 26.

Dear Editor,

COVID-19 is caused by the SARS-COV-2 virus. Causing acute respiratory syndrome, this virus has infected tens of millions of people and led to a pandemic. Following that, people were quarantined in their homes. Responses and reactions to COVID-19 appear to be widely different, ranging from asymptomatic or mild to severe conditions and death, among different people and regions (1). Numerous clinical trials worldwide have explored the efficacy of existing medicines against COVID-19, including various antiviral and immunomodulatory drugs (2). In its acute phases, when acute respiratory problems are present, N-Acetyl Cysteine and Famotidine are recommended for faster recovery of patients (3, 4). A wide variety of vaccines have been developed to fight the coronavirus. which include different platforms such as RNA, live-attenuated virus, protein subunit, and viral vector (5).

The present study evaluated and compared complications of COVID-19 vaccines and their severity among subjects taking the first dose of Sinopharm, Bharat, AstraZeneca, and Sputnik V vaccines.

This cross-sectional study was conducted in the Clinical Research Development Center of Shahid Mohammadi Hospital, in Bandar Abbas on April 2021, in Bandar Abbas, Iran, Iran with 270 people after injecting the first dose of Gam-COVID-vac, Oxford-AstraZeneca, and Bharat Biotech (Covaxin), and (Sinopharm) BBIBP-CorV. Since this study was done for the first groups of vaccinations, we used the census method for the study. An online questionnaire was designed to assess demographic information in addition to local and systemic complications of vaccination. Subjects were assessed in terms of local complications as well

as systemic complications three days after vaccination.

This study was approved by the Research Ethics Committee of Hormozgan University of Medical Sciences. Among 270 vaccinated individuals, fever (62%), anorexia (34%), nausea and vomiting (29%), myalgia (68%), and weakness (82%) were the most prevalent complications in the AstraZeneca group. Furthermore, pain at the vaccination site was also most prevalent in the AstraZeneca group (49/58 (84%).

Dorofofei and Xia reported mild to moderate pain and fever at the injection site as the most common complications of the Sinopharm vaccine, which is consistent with our findings (6,7). Zhu reported myalgia in 18%, fever in 16%, and nausea and vomiting in 6% of individuals receiving the Sinopharm vaccine. In this study, 20% of people experienced myalgia, 10% experienced fever, and 8% experienced nausea and vomiting after the first dose of the Sinopharm vaccine. In addition, Zhu et al. reported diarrhea in 8% of individuals, which was not reported in the present study (8) (Table 1).

In Dorofofei's study, 3% reported headache, 3% fatigue, 5% pain at injection site, 2% fever, and nausea and vomiting 2% in individuals receiving the first dose of Bharat vaccine while these figures were respectively 38%, 44%, 61%, 15%, and 15% in the present study. Given that Dorofofei's study population was 755 individuals, the difference in the prevalence of complications can be due to our small sample size (7).

Our study showed that among the under-examination vaccines, the most common local and general complications pertained to AstraZeneca, Sputnik V, Sinopharm, and Bharat vaccines, respectively among the first-dose vaccine recipients. Further studies and comparisons for different

vaccines are recommended with larger sample sizes in different communities after receiving the full dose of vaccines.

Footnotes

Authors' Contribution: HR.S and M.KJ contributed in conception, design and statistical analysis. Other authors contributed in data collection and manuscript drafting. M.KJ supervised the study. All authors approved the final version of the manuscript.

Conflict of Interests: The authors have no conflict of interest. All authors declare that they have no relationship with the people who were vaccinated.

Ethical Approval: IR.HUMS.REC.1399.541. Link: ethics.research.ac.ir/EthicsProposalView.php?id=181618

Funding/Support: Clinical Research Development Center of Hormozgan University of Medical Sciences, Bandar-Abbas, Iran.

References

1. Carter-Timothe ME, Jørgensen SE, Freytag MR, Thomsen MM, Brinck Andersen N, Al-Mousawi A, et al. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. *Front Immunol.* 2020;**11**. <https://doi.org/10.3389/fimmu.2020.01606>.
2. Mahmud R, Rahman MM, Alam I, Ahmed KGU, Kabir A, Sayeed S, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. *J Int Med Res.* 2021;**49**(5):3000605211013550. [PubMed: 33983065]. [PubMed Central: PMC8127799]. <https://doi.org/10.1177/03000605211013550>.
3. Rahimi A, Samimaghani HR, Azad MH, Hooshyar D, Arabi M, Kazemijahromi M. The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. *Trials.* 2021;**22**(1):271. [PubMed: 33845881]. [PubMed Central: PMC8040363]. <https://doi.org/10.1186/s13063-021-05242-4>.
4. Samimaghani HR, Hassani Azad M, Haddad M, Arabi M, Hooshyar D, Kazemijahromi M. The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. *Trials.* 2020;**21**(1):848. [PubMed: 33050945]. [PubMed Central: PMC7552598]. <https://doi.org/10.1186/s13063-020-04773-6>.
5. Soleimanpour S, Yaghoobi A. COVID-19 vaccine: where are we now and where should we go? *Expert Rev Vaccines.* 2021;**20**(1):23-44. [PubMed: 33435774]. [PubMed Central: PMC7898300]. <https://doi.org/10.1080/14760584.2021.1875824>.
6. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis.* 2021;**21**(1):39-51. [PubMed: 33069281]. [PubMed Central: PMC7561304]. [https://doi.org/10.1016/S1473-3099\(20\)30831-8](https://doi.org/10.1016/S1473-3099(20)30831-8).
7. Doroftei B, Ciobica A, Ilie OD, Maftai R, Ilea C. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. *Diagnostics (Basel).* 2021;**11**(4). [PubMed: 33804914]. [PubMed Central: PMC8063839]. <https://doi.org/10.3390/diagnostics11040579>.
8. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet.* 2020;**396**(10249):479-88. [PubMed: 32702299]. [PubMed Central: PMC7836858]. [https://doi.org/10.1016/S0140-6736\(20\)31605-6](https://doi.org/10.1016/S0140-6736(20)31605-6).

Table 1. Comparison of Adverse Reactions of Sputnik V, Oxford–AstraZeneca, Bharat, and Sinopharm Vaccines ^a

	Vaccine Type				P-Value
	Sputnik V	AstraZeneca	Bharat	Sinopharm	
Weakness					0.001
Asymptomatic	63 (53)	11 (9)	9 (7)	34 (29)	
Mild	26 (55)	8 (17)	3 (6)	10 (21)	
Moderate	32 (56)	19 (32)	1 (3)	5 (8)	
Severe	29 (59)	20 (41)	0	0	
Total	150	58	13	49	
Headache					0.031
Asymptomatic	77 (53)	19 (13)	8 (5)	39 (27)	
Mild	25 (55)	11 (24)	2 (4)	7 (15)	
Moderate	26 (60)	12 (26)	3 (6)	3 (6)	
Severe	22 (58)	16 (42)	0	0	
Myalgia					0.012
Asymptomatic	56 (48)	18 (14)	9 (7)	32 (31)	
Mild	21 (46)	8 (17)	3 (6)	13 (22)	
Moderate	43 (69)	16 (25)	1 (1)	2 (3)	
Severe	30 (62)	16 (33)	0	2 (5)	
Bone pain					0.021
Asymptomatic	73 (48)	23 (15)	12 (7)	44 (29)	
Mild	20 (55)	13 (36)	0	3 (8)	
Moderate	32 (72)	9 (20)	1 (2)	2 (4)	
Severe	25 (65)	13 (34)	0	0	
Nausea and vomiting					0.01
Asymptomatic	124 (57)	41 (18)	11 (5)	45 (20)	
Mild	11 (42)	10 (32)	1 (3)	4 (15)	
Moderate	8 (57)	5 (35)	1 (7)	0	
Severe	7 (77)	2 (33)	0	0	
Anorexia					0.017
Asymptomatic	111 (57)	28 (14)	12 (6)	45 (23)	
Mild	19 (52)	16 (43)	0	2 (5)	
Moderate	14 (50)	11 (39)	1 (3)	2 (8)	
Severe	6 (66)	3 (34)	0	0	
Sneezing					0.1
Asymptomatic	139 (57)	50 (20)	13 (4)	45 (19)	
Mild	10 (55)	4 (22)	0	4 (22)	
Moderate	0	4	0	0	
Severe	1	0	0	0	
Cough					0.001
Asymptomatic	139 (56)	47 (19)	12 (4)	47 (19)	

Mild	8 (47)	7 (43)	1 (5)	1 (5)
Moderate	3 (37)	4 (50)	0	1 (5)
Severe	0	0	0	0
Sore throat				0.021
Asymptomatic	124 (53)	46 (20)	12 (5)	47 (20)
Mild	12 (54)	7 (32)	1 (4)	2 (9)
Moderate	11 (78)	3 (22)	0	0
Severe	3 (79)	1 (25)	0	0
Fever				0.017
Asymptomatic	89 (55)	18 (9)	11 (6)	44 (27)
Mild	36 (54)	23 (34)	2 (3)	5 (7)
Moderate	13 (50)	13 (50)	0	0
Severe	12 (75)	4 (25)	0	0
Chills				0.013
Asymptomatic	92 (57)	17 (10)	10 (7)	45 (26)
Mild	16 (48)	12 (35)	2 (5)	4 (12)
Moderate	19 (59)	12 (37)	1 (2)	0
Severe	23 (57)	17 (43)	0	0
Urticaria				0.032
Asymptomatic	143 (55)	56 (21)	13 (5)	48 (18)
Mild	5 (84)	0	0	1 (16)
Moderate	1 (100)	0	0	0
Severe	1 (33)	2 (67)	0	0
Pain at injection site				0.002
Asymptomatic	43 (53)	9 (12)	5 (6)	24 (29)
Mild	47 (54)	16 (18)	5 (5)	18 (20)
Moderate	38 (57)	18 (27)	2 (3)	8 (12)
Severe	23 (60)	14 (36)	1 (4)	0
Swelling				0.021
Asymptomatic	124 (53)	48 (20)	13 (5)	45 (18)
Mild	13 (56)	6 (26)	0	4 (18)
Moderate	10 (90)	1 (10)	0	0
Severe	3 (50)	3 (50)	0	0
Discoloration				0.021
Asymptomatic	135 (55)	49 (20)	13 (5)	44 (19)
Mild	14 (73)	3 (15)	0	2 (10)
Moderate	1 (33)	2 (67)	0	0
Severe	0	0	0	0

^a Values are expressed as No. (%).